NASDAQ TRADE HALT REASON NOT AVAILABLE AT 04:00 AM
NASDAQ TRADE HALT DSGN.O REASON NOT AVAILABLE AT 04:00 AM
Recent news on Design Therapeutics
See all newsDesign Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Design Therapeutics Q2 net loss narrower than expected
Brief: Design Therapeutics Q2 Basic EPS USD -0.32
Design Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Design Therapeutics Announces Initiation Of Patient Dosing In Phase 1 Multiple Ascending Dose Trial Of Dt-818 For Myotonic Dystrophy Type-1